No connection

Search Results

GOSS

BEARISH
$0.37 Live
Gossamer Bio, Inc. · NASDAQ
Target $3.69 (+891.8%)
$0.32 52W Range $3.87

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 10, 2026
Market cap
$87.21M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.

Key Strengths

Strong YoY revenue growth of 47.10%
Healthy short-term liquidity with a Current Ratio of 2.64
Quick Ratio of 2.36 suggests immediate obligations can be met
Gross margin remains at 100%, typical for pre-commercial biotech
Positive Q/Q revenue growth trend

Key Risks

Negative Book Value (P/B -0.71) indicating liabilities exceed assets
Piotroski F-Score of 0/9 signals severe fundamental deterioration
Extreme price decay with a 5-year decline of 95.6%
Consistent quarterly losses over 25 consecutive quarters
High cash burn rate reflected in the -333.65% operating margin

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
8
Weak
Value
5
Future
30
Past
5
Health
0
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Negative equity, Zero Piotroski score, Catastrophic price performance, Chronic lack of profitability
Confidence
90%
Value
5/100

P/B of -0.71 indicates the company is technically insolvent on a balance sheet basis.

Positives
No standout positives identified.
Watchpoints
  • Negative Price/Book ratio
  • No P/E or Graham Number available due to losses
Future
30/100

Growth in revenue is irrelevant without a viable path to positive margins.

Positives
  • Strong revenue growth (47%)
Watchpoints
  • Negative YoY EPS growth (-40%)
  • Lack of a clear path to profitability
Past
5/100

Long-term historical trend is overwhelmingly bearish.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change: -95.6%
  • 6M Change: -85.5%
  • Consistent earnings misses
Health
0/100

The 0/9 F-Score is a definitive red flag for financial instability.

Positives
  • Current Ratio > 2.0
Watchpoints
  • Piotroski F-Score: 0/9
  • Negative equity
  • Severe operating losses
Dividend
0/100

Not a dividend-paying security.

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • Zero payout capacity

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.37
Analyst Target
$3.69
Upside/Downside
+891.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for GOSS and closest competitors.

Updated 2026-04-09
GOS
Gossamer Bio, Inc.
Primary
5Y
-95.6%
3Y
-66.2%
1Y
-57.8%
6M
-85.5%
1M
-26.7%
1W
+0.4%
BDS
Biodesix, Inc.
Peer
5Y
-97.8%
3Y
-75.2%
1Y
-34.9%
6M
+31.6%
1M
+72.1%
1W
+49.0%
AMW
American Well Corporation
Peer
5Y
-99.3%
3Y
-93.4%
1Y
-55.6%
6M
-45.6%
1M
+6.1%
1W
+3.4%
ASR
Assertio Holdings, Inc.
Peer
5Y
-80.4%
3Y
-85.9%
1Y
-2.8%
6M
-7.5%
1M
-1.3%
1W
-1.5%
FOR
Forian Inc.
Peer
5Y
-82.8%
3Y
-35.5%
1Y
+13.5%
6M
-7.0%
1M
+2.9%
1W
+1.9%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-2.23
PEG Ratio
N/A
P/B Ratio
-0.71
P/S Ratio
1.8
EV/Revenue
3.16
EV/EBITDA
-0.94
Market Cap
$87.21M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -333.65%
Gross Margin 100.0%
ROE N/A
ROA -41.86%

Growth

Revenue and earnings growth rates

Revenue Growth +47.1%
Earnings Growth N/A
Q/Q Revenue Growth +47.13%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
2.64
Strong
Quick Ratio
2.36
Excellent
Cash/Share
$0.58

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-333.6%
Net Margin
-342.3%
Total Assets
$0.2B
Liabilities
$0.3B
Equity
$-0.1B
Debt/Equity
-2.40x
Operating CF
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14
$N/A
2026-03-17
$-0.21
-7.3% surprise
2025-11-05
$-0.21
-6.5% surprise
2025-08-05
$-0.17
+5.8% surprise

Healthcare Sector Comparison

Comparing GOSS against 205 companies in the Healthcare sector (17 bullish, 70 neutral, 118 bearish)
Revenue Growth
47.1%
This Stock
vs
106.86%
Sector Avg
-55.9% (Slower)
Current Ratio
2.64
This Stock
vs
3.53
Sector Avg
-25.2% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

HASNAIN FAHEEM
Chief Executive Officer
Stock Award
2026-01-02
280,000 shares
GIRAUDO BRYAN M.
Chief Operating Officer
Stock Award
2026-01-02
115,750 shares
PETERSON CARYN
Officer
Stock Award
2026-01-02
84,500 shares
ARANDA RICHARD
Officer
Stock Award
2026-01-02
93,750 shares
CHRISTIAN WAAGE
Officer
Stock Award
2026-01-02
84,500 shares
SMITH ROBERT PAUL JR
Officer
Stock Award
2026-01-02
93,750 shares
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
HOLD
7 analysts
Cantor Fitzgerald
2026-03-23
down
Overweight Neutral
HC Wainwright & Co.
2026-03-06
Maintains
Buy Buy
Oppenheimer
2026-03-05
Maintains
Outperform Outperform
Wedbush
2026-02-24
down
Outperform Neutral
Barclays
2026-02-24
down
Overweight Underweight
Leerink Partners
2026-02-24
down
Outperform Market Perform
Barclays
2026-01-28
init
Overweight
HC Wainwright & Co.
2026-01-22
reit
Buy Buy

Past News Coverage

Recent headlines mentioning GOSS from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile